These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 28599900

  • 41. The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer.
    Pillai MR, Halabi S, McKalip A, Jayaprakash PG, Rajalekshmi TN, Nair MK, Herman B.
    Cancer Epidemiol Biomarkers Prev; 1996 May; 5(5):329-35. PubMed ID: 9162297
    [Abstract] [Full Text] [Related]

  • 42. Research on expression and importance of p53, p16 and VEGF-C in cervical cancer.
    Cai S, Han K.
    J Gynecol Obstet Biol Reprod (Paris); 2015 Sep; 44(7):639-45. PubMed ID: 25443468
    [Abstract] [Full Text] [Related]

  • 43. EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: implications for targeted radiotherapy.
    Shen L, Shui Y, Wang X, Sheng L, Yang Z, Xue D, Wei Q.
    BMC Cancer; 2008 Aug 12; 8():232. PubMed ID: 18700025
    [Abstract] [Full Text] [Related]

  • 44. A multimarker model to predict outcome in tamoxifen-treated breast cancer patients.
    Linke SP, Bremer TM, Herold CD, Sauter G, Diamond C.
    Clin Cancer Res; 2006 Feb 15; 12(4):1175-83. PubMed ID: 16489071
    [Abstract] [Full Text] [Related]

  • 45. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
    Tomić S, Ilić Forko J, Babić D, Sundov D, Kuret S, Andelinović S.
    Croat Med J; 2003 Aug 15; 44(4):429-34. PubMed ID: 12950146
    [Abstract] [Full Text] [Related]

  • 46. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
    Middleton LP, Amin M, Gwyn K, Theriault R, Sahin A.
    Cancer; 2003 Sep 01; 98(5):1055-60. PubMed ID: 12942575
    [Abstract] [Full Text] [Related]

  • 47. High expression of flotillin-2 is associated with poor clinical survival in cervical carcinoma.
    Liu Y, Lin L, Huang Z, Ji B, Mei S, Lin Y, Shen Z.
    Int J Clin Exp Pathol; 2015 Sep 01; 8(1):622-8. PubMed ID: 25755754
    [Abstract] [Full Text] [Related]

  • 48. Expression of survivin, CD117, and C-erbB-2 in neuroendocrine carcinoma of the uterine cervix.
    Sukpan K, Settakorn J, Khunamornpong S, Cheewakriangkrai C, Srisomboon J, Siriaunkgul S.
    Int J Gynecol Cancer; 2011 Jul 01; 21(5):911-7. PubMed ID: 21633298
    [Abstract] [Full Text] [Related]

  • 49. Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations.
    Mafficini A, Amato E, Cataldo I, Rusev BC, Bertoncello L, Corbo V, Simbolo M, Luchini C, Fassan M, Cantù C, Salvia R, Marchegiani G, Tortora G, Lawlor RT, Bassi C, Scarpa A.
    Ann Surg; 2018 Jan 01; 267(1):149-156. PubMed ID: 27611608
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. p53-independent growth regulation of cervical cancer cells by the papillomavirus E6 oncogene.
    Spitkovsky D, Aengeneyndt F, Braspenning J, von Knebel Doeberitz M.
    Oncogene; 1996 Sep 05; 13(5):1027-35. PubMed ID: 8806692
    [Abstract] [Full Text] [Related]

  • 52. Expression of c-myc, epidermal growth factor receptor and c-erbB-2 in human endometrial carcinoma and cervical adenocarcinoma.
    Sato S, Ito K, Ozawa N, Yajima A, Sasano H.
    Tohoku J Exp Med; 1991 Oct 05; 165(2):137-45. PubMed ID: 1687493
    [Abstract] [Full Text] [Related]

  • 53. EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis.
    Ettl T, Stiegler C, Zeitler K, Agaimy A, Zenk J, Reichert TE, Gosau M, Kühnel T, Brockhoff G, Schwarz S.
    Hum Pathol; 2012 Jun 05; 43(6):921-31. PubMed ID: 22154363
    [Abstract] [Full Text] [Related]

  • 54. Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing.
    Cho SY, Choi M, Ban HJ, Lee CH, Park S, Kim H, Kim YS, Lee YS, Lee JY.
    Oncotarget; 2017 Jan 31; 8(5):8095-8104. PubMed ID: 28042953
    [Abstract] [Full Text] [Related]

  • 55. Cluster of differentiation 24 expression is an independent prognostic factor of adverse outcome in cervical carcinoma.
    Huang LW, Lee CC.
    Int J Gynecol Cancer; 2013 Feb 31; 23(2):325-30. PubMed ID: 23318912
    [Abstract] [Full Text] [Related]

  • 56. A 10-gene prognostic signature points to LIMCH1 and HLA-DQB1 as important players in aggressive cervical cancer disease.
    Halle MK, Sødal M, Forsse D, Engerud H, Woie K, Lura NG, Wagner-Larsen KS, Trovik J, Bertelsen BI, Haldorsen IS, Ojesina AI, Krakstad C.
    Br J Cancer; 2021 May 31; 124(10):1690-1698. PubMed ID: 33723390
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis.
    Valgardsdottir R, Tryggvadottir L, Steinarsdottir M, Olafsdottir K, Jonasdottir S, Jonasson JG, Ogmundsdottir HM, Eyfjörd JE.
    APMIS; 1997 Feb 31; 105(2):121-30. PubMed ID: 9113074
    [Abstract] [Full Text] [Related]

  • 60. p53 tumor suppressor gene protein expression in cervical cancer: relationship to prognosis.
    Bremer GL, Tieboschb AT, van der Putten HW, de Haan J, Arends JW.
    Eur J Obstet Gynecol Reprod Biol; 1995 Nov 31; 63(1):55-9. PubMed ID: 8674566
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.